What drinking 3 cups of coffee daily did to a study group of more than 170,000 people
Drinking too much coffee has a reputation of being harmful, but a new study says having three cups a day can lower the risk of developing more than one cardiometabolic disease.
Bristol-Myers Stock Jumps on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
She took Ozempic, now she can't eat without vomiting. Lawsuit claims the drug made her ill
Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.
STAT2h
Dispute over Duchenne gene therapy highlights thorny access issues
A dispute over a Duchenne gene therapy highlights thorny issues surrounding FDA approvals and insurance policies.
This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
FDA approves 1st new drug to treat schizophrenia in more than 30 years
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years.
Food Safety News7h
Patient count in Cyclospora outbreak increases; other outbreaks hold steady
The number of confirmed patients in an outbreak of infections from the Cyclospora parasite continues to increase, with 60 ...
US FDA approves Bristol Myers' schizophrenia drug
Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last ...
FDA approves new schizophrenia drug
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
health.wusf.usf.edu10h
The FDA approves a new type of schizophrenia drug
The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic
Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...
FDA approves schizophrenia drug
The U.S. Food and Drug Administration has granted approval to Cobenfy, the first new schizophrenia drug in decades.